A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects

NCT03836599 | Completed Phase 1 FDA Drug

• 1 other identifier: D5495C00006
• Study Type: interventional
• Target: 6
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized, placebo controlled, double-blind study with two separate cohorts to assess safety, tolerability and pharmacokinetics of verinurad and allopurinol in healthy subjects. In cohort 1, twelve Asian subjects will be treated with allopurinol 300mg for 7 days followed by either allopurinol 300mg and verinurad 24mg or matching placebo for 7 days. In Cohort 2, nine Chinese subjects will be treated with allopurinol 300mg for 7 days followed by allopurinol 300mg and verinurad 12mg administered on 7 out of 8 days.

Conditions

Chronic Kidney Disease

Keywords

Uric acid transporter 1 (URAT1) Inhibitor; Xantine oxidoreductase inhibitor; Pharmacokinetics; Verinurad; Allopurinol

Outcome Measures

Primary Outcomes (14)

• Number of participants with adverse events

  To assess the safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants.

  From screening up to Follow-up visit/Early discontinuation visit (EDV) (7-14 Days Post-last PK Sample)

• Number of participants with abnormal findings in electrocardiography (ECG)

  To assess abnormal resting digital 12-lead electrocardiograms as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants.

  From screening up to Follow-up visit/EDV (7-14 Days Post-last PK Sample)

• Number of participants with abnormal pulse rate

  To assess abnormal pulse rate as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants.

  From screening up to Follow-up visit/EDV (7-14 Days Post-last PK Sample)

• Number of participants with abnormal hematology

  To assess white blood cell count (WBC), red blood cell count (RBC), neutrophils absolute count, lymphocytes absolute count, monocytes absolute count, eosinophils absolute count, basophils absolute count, platelets, and reticulocytes absolute count as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants.

  From screening up to Follow-up visit/EDV (7-14 Days Post-last PK Sample)

• Number of participants with abnormal blood pressure (systolic and diastolic)

  To assess abnormal blood pressure (systolic and diastolic) as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants.

  From screening up to Follow-up visit/EDV (7-14 Days Post-last PK Sample)]

• Number of participants with abnormal physical examination

  To assess safety and tolerability by assessment of the general appearance, respiratory, cardiovascular, abdomen, skin, head, and neck (including ears, eyes, nose, and throat), lymph nodes, thyroid, musculoskeletal and neurological systems.

  From screening up to Follow-up visit/EDV (7-14 Days Post-last PK sample)]

• Number of participants with abnormal electrolytes

  To assess serum level of sodium, potassium, calcium (total), and phosphate as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants.

  From screening up to Follow-up visit/EDV (7-14 Days Post-last PK smaple)]

• Number of participants with abnormal hemoglobin (Hb)

  To assess Hb as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants.

  From screening up to Followup visit/EDV (7-14 Days Postlast PK Sample)

• Number of participants with abnormal hematocrit

  To assess hematocrit as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants.

  From screening up to Followup visit/EDV (7-14 Days Postlast PK Sample)

• Number of participants with abnormal Mean corpuscular volume (MCV)

  To assess MCV as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants.

  From screening up to Followup visit/EDV (7-14 Days Postlast PK Sample)

• Number of participants with abnormal mean corpuscular hemoglobin (MCH)

  To assess MCH as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants.

  From screening up to Followup visit/EDV (7-14 Days Postlast PK Sample)

• Number of participants with abnormal mean corpuscular hemoglobin concentration (MCHC)

  To assess MCHC as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants.

  From screening up to Followup visit/EDV (7-14 Days Postlast PK Sample)

• Number of participants with abnormal clinical chemistry

  To assess the safety and tolerability profile of verinurad and allopurinol treatment in terms of the number of participants with abnormal clinical chemistry values. The laboratory variables to be measured are: bilirubin, creatinine, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), cystatin C, gamma glutamyl transpeptidase, urea and uric acid.

  From screening up to Follow-up visit/EDV (7-14 Days Post-last PK Sample)

• Number of participants with abnormal urinalysis.

  To assess the safety and tolerability profile of verinurad and allopurinol treatment in terms of the number of participants with abnormal urinalysis values. The laboratory variables to be measured are: protein, glucose, blood, uric acid, pH, sodium, creatinine, and cystatin C.

  From screening up to Follow-up visit/EDV (7-14 Days Post-last PK Sample)

Secondary Outcomes (10)

• Area under plasma concentration-time curve from zero to infinity (AUC), AUC(0-t), AUC(0-24), and AUCτ

  On Day 1, Days 3 to 6, Day 7 (cohort 1). On Day 1, Day 2, Days 3 to 8, and Day 9 (Cohort 2).

• Observed concentration and percentage change from baseline in serum uric acid

  On Day -1: -24, -21, -18, and -12 hours prior to dosing on Day 1. On Days 1, 7 and 9 (Pre-dose, 3, 6, 12, and 24 hours post-dose).

• Observed concentration and percentage change from baseline in urine uric acid

  On Day -1: baseline collection of urine: -24 to -22 h, -22 h to -20 h, -18 h to -16 h, -16 h to - 12 h and -12 h to 0 h prior to dosing on Day 1, on Days 1, 7 and 9 (0-2 h, 2-4 h, 4-6 h, 6-8 h, 8-12 h, and 12-24 h post-dose).

• Maximum observed plasma concentration (Cmax) and Minimum observed plasma concentration (Cmin)

  On Day 1, Days 3 to 6, Day 7(cohort 1). On Day 1, Day 2, Days 3 to 8, and Day 9 (Cohort 2)

• Time to reach maximum observed plasma concentration (tmax) and Time of last measurable concentration (tlast)

  On Day 1, Days 3 to 6, Day 7 (cohort 1). On Day 1, Day 2, Days 3 to 8, and Day 9 (Cohort 2).

Study Arms (3)

24 mg Verinurad+300 mg allopurinol

EXPERIMENTAL

During Run-in Period, participants will be dosed with 300 mg of allopurinol from Day -7 to Day -1. During the Treatment Period, participants will be administered 24 mg verinurad with 300 mg allopurinol once daily on Days 1 to 7.

Drug: Verinurad; Drug: Allopurinol

12 mg Verinurad+300 mg allopurinol

EXPERIMENTAL

During Run-in Period, participants will be dosed with 300 mg of allopurinol once daily from Day -7 to Day -1. During Treatment Period, participants will receive a single dose of 12 mg verinurad and 300 mg allopurinol on Day 1. No dosing will be done on Day 2. Participants will continue dosing on Day 3 and will be dosed once daily until Day 9.

Drug: Verinurad; Drug: Allopurinol

Placebo

PLACEBO COMPARATOR

During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.

Drug: Placebo

Interventions

Verinurad DRUG

Participants will receive verinurad 24 mg in cohort 1 and 12 mg in cohort 2 once daily.

12 mg Verinurad+300 mg allopurinol; 24 mg Verinurad+300 mg allopurinol

Allopurinol DRUG

Participants will receive allopurinol 300 mg once daily.

12 mg Verinurad+300 mg allopurinol; 24 mg Verinurad+300 mg allopurinol

Placebo DRUG

During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.

Placebo

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Provision of signed and dated, written informed consent prior to any study specific procedures.
• Applicable only to Cohort 1: Healthy male and female Asian subjects aged 18 to 50 years (inclusive) at the Screening Visit with suitable veins for cannulation or repeated venipuncture. A subject will be considered Asian if the subject and both of the subject's parents are part of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent, including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam).
• Applicable only to Cohort 2: Healthy male and female Chinese subjects aged 18 to 50 years (inclusive) at the Screening Visit with suitable veins for cannulation or repeated venipuncture. A subject will be considered Chinese if:
• Both parents and all grandparents are Chinese, and
• Subject was born in China, and
• Subject has not lived outside China for more than 10 years.
• Subject has a sUA acid level \> 4.0 mg/dL at the Screening Visit. The assessment may be repeated once during the Screening Period.
• Females must have a negative pregnancy test at the Screening Visit and Day -7, must not be lactating and must be:
• Of non-childbearing potential, confirmed at the Screening Visit by fulfilling one of the following criteria:
• Post-menopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and Follicle-stimulating hormone (FSH) levels in the post-menopausal range (FSH levels \> 40 IU/mL).
• Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
• OR if of childbearing potential must be willing to use an acceptable method of contraception to avoid pregnancy for the entire study period.

You may not qualify if:

• Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, at the Screening Visit as judged by the Investigator including:
• Alanine aminotransferase (ALT) \>1.5 x upper limit of normal (ULN);
• Aspartate aminotransferase (AST) \>1.5 x ULN;
• Bilirubin (total) \> 1.5 x ULN; and
• Gamma glutamyl transpeptidase (GGT) \>1.5 x ULN. If any these tests are out-of-range the test can be repeated once at the Screening Visit at the discretion of the Investigator.
• Known carrier of the Human Leukocyte Antigen-B (HLA-B) \*58:01 allele.
• Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.
• Suspected or known Gilbert's syndrome.
• Current smokers or those who have smoked or used nicotine products (including e-cigarettes within the previous 3 months).
• Positive screen for drugs of abuse, cotinine (nicotine) or alcohol at the Screening Visit or on Day -7.
• Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of investigational product or within 5 half-lives (whichever is longer). The use of hormonal contraception therapy and hormonal replacement therapy for females are permitted.
• Has received another new chemical or biological entity (defined as a compound which has not been approved for marketing in the US) within 30 days or within 5 half-lives (whichever is longer) of the first administration of investigational drug in this study.
• Involvement of any AstraZeneca, PAREXEL or study site employee or their close relatives.
• Subjects who are vegans or have medical dietary restrictions.

Sponsors & Collaborators

• AstraZeneca: lead
• Parexel: collaborator

Study Sites (1)

Research Site

Glendale, California, 91206, United States

Location

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Interventions

verinurad; Allopurinol

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• David Han, MD

  Parexel

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: Cohort 1 is double blind Cohort 2 is open-label
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 21, 2018
• First Posted: February 11, 2019
• Study Start: January 16, 2019
• Primary Completion: April 26, 2019
• Study Completion: April 26, 2019
• Last Updated: May 13, 2019

Record last verified: 2019-05

Locations

US (1)